Insurance and At-Home Ketamine Therapy: Coverage Explained

How Insurance Currently Approaches At-Home Ketamine Therapy

Most insurance plans do not provide direct coverage for at-home ketamine therapy. The reasons are structural, not medical.

The lack of coverage is tied to how the medication is classified by regulatory agencies. Ketamine has been FDA-approved as an anesthetic since 1970,² but using it for depression, anxiety, and PTSD is considered off-label prescribing (it has also been on the World Health Organization List of Essential Medicines since 1985¹).

Off-label prescribing is a widespread and legally accepted medical practice that accounts for approximately 21% of all outpatient prescriptions across medical specialties.³

Because at-home ketamine for mental health conditions is off-label, most insurance formularies exclude it. The coverage gap is a structural issue within the insurance industry rather than a reflection of medical legitimacy. Several reimbursement and payment options remain available.

Key reasons coverage is limited:

• Off-label status: The FDA approved ketamine only as an anesthetic, meaning mental health use is off-label.
• Formulary exclusion: Most plan formularies do not list compounded or oral ketamine for psychiatric indications.
• No billing pathway: At-home administration lacks the facility and procedure codes that in-clinic treatments use for claims.

How Insurance Coverage Differs by Type of Ketamine Therapy

Coverage depends heavily on the type of ketamine treatment and how it is administered. The following sections explain how insurance treats each specific modality.

At-Home Ketamine Therapy

At-home ketamine therapy typically involves tablets, troches, or subcutaneous injections prescribed by a licensed provider. Patients take the medication at home under a defined treatment framework. Some at-home ketamine programs, including Mindbloom, require a peer session monitor to be present during every session.

Because the treatment uses compounded racemic ketamine prescribed off-label, it is not covered by the vast majority of insurance plans. Compounded ketamine has not undergone FDA review for safety, effectiveness, or manufacturing consistency, so it should be used only under clinician oversight and supplied by a regulated U.S. compounding pharmacy.^4,5

Those utilizing sublingual ketamine typically pay out-of-pocket and seek partial reimbursement through out-of-network claims.

IV Ketamine Infusions

Intravenous (IV) ketamine is administered in a care setting, typically over 40 to 60 minutes per session. Like sublingual tablets, IV ketamine is prescribed off-label for mental health conditions and is generally not covered by insurance.

The IV modality carries additional costs beyond the medication itself. The total bill often includes clinic facility fees, specialist monitoring fees, and travel expenses. Some clinics bill associated services separately, such as the initial consultation, which may be partially reimbursable.

IV ketamine is an established modality, but the combination of off-label status and layered clinic costs means most patients pay entirely out-of-pocket.

Spravato (Esketamine) Nasal Spray

Spravato is an FDA-approved esketamine nasal spray manufactured by Janssen. It is administered in a certified healthcare setting under the Risk Evaluation and Mitigation Strategy (REMS) program.

Because it has FDA approval specifically for treatment-resistant depression, it is covered by many commercial insurance plans and Medicare Part B. Approval typically requires documented failure of two or more antidepressant trials, and the patient must meet additional inclusion criteria. Sessions must occur in a REMS-certified facility with a two-hour post-dose monitoring period.

Having an insurance benefit does not always mean the treatment is easily accessible. The eligibility requirements, in-clinic administration mandate, and prior authorization process create barriers for many people who might otherwise benefit.

Common Spravato coverage requirements:

• Diagnosis: Treatment-resistant depression or major depressive disorder with acute suicidal ideation.
• Prior treatment failure: Typically two or more adequate antidepressant trials.
• Administration setting: REMS-certified facility with post-dose monitoring.
• Prior authorization: Required by most plans before coverage is confirmed.

Ketamine-Assisted Psychotherapy

Ketamine-assisted psychotherapy is a treatment model where ketamine is administered alongside talk therapy.

The psychotherapy component may be billed separately under standard mental health CPT codes. Some plans reimburse the therapy portion even when the ketamine medication itself is not covered.

Reimbursement depends on the provider's credentials, their network status, and your specific mental health benefits. Ask your provider whether the therapy sessions qualify for reimbursement independently of the medication.

Coverage Differences by Insurance Plan Type

Even within the same treatment modality, coverage varies significantly by the type of insurance plan. Below is an overview of what patients can generally expect from major plan categories.

Commercial Insurance (Blue Cross Blue Shield, UnitedHealthcare, Aetna, Kaiser)

Commercial insurance includes employer-sponsored and individual marketplace plans from major carriers. Most commercial plans do not cover off-label racemic ketamine for mental health conditions.

Some plans cover Spravato if the patient meets treatment-resistant depression criteria and obtains prior authorization. Out-of-network benefits vary significantly by carrier and plan tier.

Review your specific plan documents rather than relying on carrier-level generalizations. Contact your plan's member services line directly to ask specifically about ketamine and esketamine coverage, including out-of-network reimbursement policies.

Medicare

Medicare Part B may cover Spravato when it is administered in a REMS-certified facility for an approved indication. Off-label racemic ketamine, whether administered via IV or at home, is generally not a Medicare-covered benefit.

Coverage details can also vary by specific Medicare Advantage plans. Beneficiaries should verify benefits with their specific plan administrator. Spravato reimbursement still requires meeting strict eligibility criteria.

Medicaid

Medicaid coverage varies widely from state to state. Some state Medicaid programs reimburse Spravato under prior authorization for treatment-resistant depression.

Off-label ketamine is rarely covered by Medicaid programs. Contact your state Medicaid office or managed care organization directly to get the most current formulary information.

VA and TRICARE Benefits

The Veterans Affairs (VA) healthcare system has used ketamine in some care settings for treatment-resistant depression. The VA may also cover Spravato at specific VA medical centers.

TRICARE coverage for ketamine is highly limited and generally does not extend to at-home or off-label formulations. Veterans and service members should check with their VA provider or TRICARE regional contractor for current benefit details.

What At-Home Ketamine Therapy Costs Without Insurance Coverage

At-home ketamine programs typically charge a flat rate per program or session. The single price generally includes the medication, medical oversight, and ongoing support services.

At-home sublingual ketamine is generally less expensive per session than IV infusions. In-clinic IV treatments layer facility fees, provider monitoring fees, and travel costs on top of the medication cost.

Flat-rate pricing removes the billing unpredictability that insurance-dependent models often create.

How to Check Insurance Coverage for At-Home Ketamine Therapy

A 15-minute call to your insurer before starting treatment can prevent unexpected bills and clarify your financial obligations.

Steps to verify your coverage:

• Review your plan's mental health and out-of-network benefits: Look at your Summary of Benefits and Coverage document for mental health parity provisions and out-of-network reimbursement rates.
• Call your insurer's member services line: Ask specifically whether racemic ketamine or esketamine is on the formulary, whether out-of-network mental health claims are reimbursable, and what documentation is required.
• Ask whether superbills are accepted for reimbursement: Some plans reimburse out-of-network claims when the patient submits a superbill with appropriate diagnosis and procedure codes.
• Save claim reference numbers and written responses: Document every conversation with your insurer in case of future disputes.

How Reimbursement Works for At-Home Ketamine Therapy

Even when insurance does not cover at-home ketamine directly, several reimbursement and payment mechanisms exist. These options can reduce your out-of-pocket costs, particularly when HSA or FSA pre-tax savings are combined with out-of-network reimbursement.

Submit Out-of-Network Claims with a Superbill

When your provider issues a superbill, it includes diagnosis codes (ICD-10), procedure codes (CPT), provider credentials, and session dates. It provides all the medical information an insurance company needs to process a claim.

The patient receives the superbill from their at-home ketamine provider and submits it to their insurer for out-of-network reimbursement consideration. Reimbursement amounts depend entirely on the plan's out-of-network benefit structure and allowed amounts.

Confirm your out-of-network benefits before submitting paperwork — without those benefits, the claim has no reimbursement path.

Use Your HSA or FSA When Reimbursement Is Not Available

Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) allow patients to pay for qualified medical expenses using pre-tax dollars. Paying with pre-tax funds provides a built-in financial discount based on your tax bracket.

Ketamine therapy prescribed by a licensed provider for a diagnosed medical condition generally qualifies as a medical expense under IRS guidelines. Retain all documentation, including the prescription, diagnosis records, and itemized receipts.

The tax advantage of HSA or FSA funds reduces your net cost even when your health plan provides zero direct reimbursement.

Track Deductibles and Out-of-Pocket Maximums for Reimbursement

Before insurance begins sharing costs, you must first meet your deductible. Once your spending hits the annual out-of-pocket maximum, the plan covers all remaining eligible expenses.

Out-of-network claims for ketamine therapy may count toward these thresholds depending on the specific plan rules. Anyone already close to meeting their deductible or out-of-pocket maximum may receive higher reimbursement rates for subsequent claims.

Tracking these numbers throughout the year can help patients time their claims strategically. Reviewing your Explanation of Benefits regularly ensures your spending is recorded correctly.

What to Do if Insurance Does Not Cover At-Home Ketamine Therapy

If your plan does not cover at-home ketamine and reimbursement is not available, you still have options. There are steps you can take to reduce costs or improve your future coverage.

Appeal the Denial with Supporting Documentation

If your insurer refuses to pay for a submitted service, the resulting claim denial may or may not be appealable. It is important to distinguish between a structural non-coverage determination, where the plan simply does not include the benefit, and an appealable denial, where the plan covers the category but denied the specific claim.

For appealable denials, patients can submit a formal appeal. An appeal usually requires a letter from the prescribing clinician explaining medical necessity, relevant documentation, and peer-reviewed evidence supporting ketamine therapy for the diagnosed condition.

Appeals are most effective when the denial is based on medical necessity rather than a strict formulary exclusion.

Ask Your Employer Whether Additional Mental Health Benefits Are Available

Some employers offer supplemental mental health benefits that operate outside of standard health insurance. Employee Assistance Programs (EAPs) or wellness stipends may apply to ketamine therapy costs.

Human resources departments can also advocate for expanded plan coverage during annual benefits negotiations, particularly at larger organizations where benefits packages are renegotiated each year.

Compare Plan Options During Open Enrollment When Coverage Is a Priority

If you anticipate ongoing ketamine therapy, evaluate new plan options during the annual open enrollment period. It is helpful to pay specific attention to out-of-network reimbursement rates, mental health parity provisions, and HSA eligibility.

Choosing a plan with stronger out-of-network benefits can meaningfully change the net cost of treatment over a full year. Paying a slightly higher monthly premium for better out-of-network coverage often saves money in the long run.

How Mindbloom Makes At-Home Ketamine Therapy Accessible Without Insurance

Insurance complications often create cost unpredictability for people seeking mental health care. Mindbloom's care model is designed to eliminate that unpredictability while delivering measurable results: in a peer-reviewed study of 1,247 Mindbloom clients, 89% reported symptom improvement for depression and anxiety.⁶

Transparent Flat-Rate Pricing with No Surprise Bills

Mindbloom offers programs of 6, 12, or 18 sessions. After you select a program, a licensed provider conducts a comprehensive medical evaluation to confirm your eligibility and personalize your care plan.

Mindbloom's at-home ketamine therapy starts at $165 per session for an 18-session new client program, billed in monthly installments. A 6-session new client program is $215 per session, billed as $430 per month for 3 months. Returning clients receive preferred pricing and pay as little as $129 per session with an 18-session program.

The flat rate includes medical consults, ketamine treatments, guide coaching sessions, unlimited guide messaging, unlimited Group Integration Circles, and access to the Mindbloom App. There are no separate facility fees, medication markups, or hidden charges.

HSA and FSA Accepted

Mindbloom accepts HSA and FSA payments for all treatment programs. Accepting pre-tax funds directly addresses the payment barrier for individuals whose insurance does not reimburse at-home ketamine.

Mindbloom provides the documentation you need to use these accounts. The provided itemized receipts and medical records satisfy standard IRS documentation requirements.

Medical Oversight and Integration Support Included in the Price

The cost of a Mindbloom program reflects a comprehensive care model, not just medication delivery. As outlined above, the flat rate covers all medical, coaching, and integration components. The care model also includes the Bloombox experiential toolkit.

Mindbloom is also the only at-home ketamine provider offering subcutaneous administration (Injectables) in addition to sublingual tablets. In a peer-reviewed study of 11,441 Mindbloom clients, 56.4% of depression clients met criteria for response and 28.1% met criteria for remission.⁷

Get started to learn whether Mindbloom's at-home ketamine therapy program is right for you.

Conclusion

Most insurance plans do not cover at-home racemic ketamine therapy due to its off-label status. However, reimbursement pathways, HSA and FSA accounts, and transparent flat-rate pricing models exist to make treatment accessible. Verify your specific plan's out-of-network benefits and explore all available reimbursement options before beginning care.

Important Safety Information

Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

Off-Label Use Disclosure

Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.